Pharmathene(PIP)高管介绍_美股行情_同花顺金融网

来自 : stockpage.10jqka.com.cn/PIP/ma 发布时间：2021-03-25

David J. Drutz.自2011年12月起，他担任我们的行政总裁；自2012年5月起，担任我们的首席医疗官；自2008年2月起，担任本公司董事会的成员。他目前就职于Gentris公司的董事会，这是一家药物基因（PGx）服务公司和Vaxin公司— 一家疫苗开发公司。2000年至2010年，他担任MethylGene公司的董事，这是一家以肿瘤科为重点的生物制药公司（TSX代号：MYG），并为Tranzyme制药公司的董事会主席（纳斯达克股票代码：TZYM）。他曾是环太平洋风险投资公司（日本东京）的一个普通合伙人——这是一家风险投资公司，专注于全球生物技术的投资机会。自1999年起，他还一直是太平洋生物制药协会（一家生物技术咨询公司）的总裁。他曾任副生物科学（药物发现）的总裁；普鲁士国王史克和法国实验室临床研究（艾滋病疗法）的副总裁；新泽西州Ft. Lee第一制药公司临床开发的副总裁。在第一制药公司，他负责抗感染和肿瘤产品的开发。1990年他离开第一制药公司，进入生物技术产业。 在加盟PRV之前，他曾担任启发制药公司的总裁兼行政总裁，该公司专门从事治疗呼吸道和其他黏膜表面的疾病（纳斯达克股票代码：ISPH）。他获得路易斯维尔大学医学博士学位和范德比尔特大学医学培训的研究生学位，随后他曾担任在亚洲的美国海军医务人员。他担任过加州大学旧金山、德州大学、宾夕法尼亚大学的高级教师职位。他是内科委员会认证的；美国医师学院和美国传染病学会的资深会员。

David J. Drutz has served as a member of our Board of Directors since May 2017 when he was appointed to the Board in connection with the completion of the Merger. Dr. Drutz was first elected to Private Altimmune s Board of Directors in January 2010 and was elected Board Chairman in October 2011. Dr. Drutz is the President of Pacific Biopharma Associates, LLC, a biopharmaceutical consulting company that he founded in 1999. From 2008 to 2015 he held various positions at DARA BioSciences, an oncology supportive care company which was acquired by Midatech Pharma plc, including Director, Chief Executive Officer, Executive Chairman and Chief Medical Officer. He also previously served as Chairman of Tranzyme Nasdaq:TZYM from 2000 to 2010; and Director of MethylGene (TSX:MYG) from 2000 to 2010 and Gentris Corporation from 2007 to 2014. From 1999 to 2008 he was a general partner with Pacific Rim Ventures, a Tokyo-based venture capital firm. Dr. Drutz s management experience includes tenures as VP Biological Sciences and VP Clinical Research at Smith Kline & French Laboratories; VP Clinical Development at Daiichi Pharmaceutical Corporation; and CEO of Inspire Pharmaceuticals (1995-1998) and Sennes Drug Innovations (1994-1995). Earlier, Dr. Drutz was Professor of Medicine, Chief of the Division of Infectious Diseases, and the founder of the NSF Center for Cell Regulation at the UT Health Science Center, San Antonio. Dr. Drutz received his M.D. from the University of Louisville School of Medicine and postgraduate training in internal medicine and infectious diseases at Vanderbilt University School of Medicine, serving subsequently as a research medical officer in the U.S. Navy (LCDR, USNR). He is certified by the American Board of Internal Medicine; a fellow of the American College of Physicians and the Infectious Diseases Society of America; a member of Alpha Omega Alpha, the American Society of Clinical Oncology and the American Society for Clinical Investigation; and the author of more than 200 peer-reviewed publications in the area of infectious diseases. David J. Drutz.自2011年12月起，他担任我们的行政总裁；自2012年5月起，担任我们的首席医疗官；自2008年2月起，担任本公司董事会的成员。他目前就职于Gentris公司的董事会，这是一家药物基因（PGx）服务公司和Vaxin公司— 一家疫苗开发公司。2000年至2010年，他担任MethylGene公司的董事，这是一家以肿瘤科为重点的生物制药公司（TSX代号：MYG），并为Tranzyme制药公司的董事会主席（纳斯达克股票代码：TZYM）。他曾是环太平洋风险投资公司（日本东京）的一个普通合伙人——这是一家风险投资公司，专注于全球生物技术的投资机会。自1999年起，他还一直是太平洋生物制药协会（一家生物技术咨询公司）的总裁。他曾任副生物科学（药物发现）的总裁；普鲁士国王史克和法国实验室临床研究（艾滋病疗法）的副总裁；新泽西州Ft. Lee第一制药公司临床开发的副总裁。在第一制药公司，他负责抗感染和肿瘤产品的开发。1990年他离开第一制药公司，进入生物技术产业。 在加盟PRV之前，他曾担任启发制药公司的总裁兼行政总裁，该公司专门从事治疗呼吸道和其他黏膜表面的疾病（纳斯达克股票代码：ISPH）。他获得路易斯维尔大学医学博士学位和范德比尔特大学医学培训的研究生学位，随后他曾担任在亚洲的美国海军医务人员。他担任过加州大学旧金山、德州大学、宾夕法尼亚大学的高级教师职位。他是内科委员会认证的；美国医师学院和美国传染病学会的资深会员。 David J. Drutz has served as a member of our Board of Directors since May 2017 when he was appointed to the Board in connection with the completion of the Merger. Dr. Drutz was first elected to Private Altimmune s Board of Directors in January 2010 and was elected Board Chairman in October 2011. Dr. Drutz is the President of Pacific Biopharma Associates, LLC, a biopharmaceutical consulting company that he founded in 1999. From 2008 to 2015 he held various positions at DARA BioSciences, an oncology supportive care company which was acquired by Midatech Pharma plc, including Director, Chief Executive Officer, Executive Chairman and Chief Medical Officer. He also previously served as Chairman of Tranzyme Nasdaq:TZYM from 2000 to 2010; and Director of MethylGene (TSX:MYG) from 2000 to 2010 and Gentris Corporation from 2007 to 2014. From 1999 to 2008 he was a general partner with Pacific Rim Ventures, a Tokyo-based venture capital firm. Dr. Drutz s management experience includes tenures as VP Biological Sciences and VP Clinical Research at Smith Kline & French Laboratories; VP Clinical Development at Daiichi Pharmaceutical Corporation; and CEO of Inspire Pharmaceuticals (1995-1998) and Sennes Drug Innovations (1994-1995). Earlier, Dr. Drutz was Professor of Medicine, Chief of the Division of Infectious Diseases, and the founder of the NSF Center for Cell Regulation at the UT Health Science Center, San Antonio. Dr. Drutz received his M.D. from the University of Louisville School of Medicine and postgraduate training in internal medicine and infectious diseases at Vanderbilt University School of Medicine, serving subsequently as a research medical officer in the U.S. Navy (LCDR, USNR). He is certified by the American Board of Internal Medicine; a fellow of the American College of Physicians and the Infectious Diseases Society of America; a member of Alpha Omega Alpha, the American Society of Clinical Oncology and the American Society for Clinical Investigation; and the author of more than 200 peer-reviewed publications in the area of infectious diseases.